about
The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatmentSublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil ActivationRole of mast cells in mucosal diseases: current concepts and strategies for treatment.Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease.The long and winding road to IgA deficiency: causes and consequences.Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells.Use of ICAM-1 antibodies and antisense oligonucleotides to inhibit transmigration of neutrophils.A modified method for isolating viable alveolar type II cells from human lung tissue.The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant.Antioxidant defence during cardiopulmonary bypass surgery.Mast cell subtypes from human lung tissue: their identification, separation, and functional characteristics.Toxicological assessment of kretek cigarettes Part 5: mechanistic investigations, inhalation toxicity.Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.Segmental allergen challenge induces plasma protein leakage into the airways of asthmatic subjects at 4 hours but not at 5 minutes after challengeSynergism between interleukin-1 beta and interferon-gamma, an inducer of nitric oxide synthase, in rat lung fibroblastsSoybean trypsin inhibitor and beta-amylase induce alveolar macrophages to release nitrogen oxidesTumour necrosis factor stimulates human skin mast cells to release histamine and tryptaseL-arginine-dependent production of nitrogen oxides by rat pulmonary macrophagesMediator release from human lung mast cell subtypes in chronic bronchitis and emphysemaMuramyldipeptide and granulocyte-macrophage colony-stimulating factor enhance interferon-gamma-induced nitric oxide production by rat alveolar macrophagesPlasma protein leakage and local secretion of proteins assessed in sputum in asthma and COPD. The effect of inhaled corticosteroidsPotential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injuryEvidence for marked eosinophil degranulation in a case of eosinophilic pneumoniaN-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluidAngiotensin-converting enzyme activity in serum and bronchoalveolar lavage fluid after damage to the alveolo-capillary barrier in the human lungOxidatively modified proteins in bronchoalveolar lavage fluid of patients with ARDS and patients at-risk for ARDSMore or lessDeath and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy
P50
Q31141977-062AE008-9B40-4018-993E-618498886488Q35179153-354B47E2-DDDB-41DF-9787-3ED38815A40DQ37653676-3F647AE4-3858-4A00-8A28-D3ABBABB2210Q38068961-5041F568-F6EC-489D-820F-99604B6C61CEQ38156225-C1F9AA56-7046-496E-8E0E-DD51FF0EEF69Q38989513-1DAB724F-03BF-401A-BAD0-624145074483Q40629672-8DC2DDA6-7C2F-42AC-A574-9B302D2FC775Q44827457-42B0B5BA-1DCC-422C-8DF8-3C693AE8A39AQ45012588-C8697DD1-635D-4C31-95B8-86DE2C9153C1Q45268723-D082C94E-607E-4064-B00D-12583540377EQ46398123-D5C9F56A-17AE-4659-968F-54642CB4F725Q50897093-0D15FD7C-62FC-42B9-9165-5CCB39AAB66BQ51679143-F4E57984-F53D-4013-8F74-15E531363667Q55267236-1C31E771-0795-4692-BF92-9E0003FF19D7Q61601428-4F53C867-5E94-49F5-8825-CE720B9C94B3Q67464846-771CD295-07BC-40B9-8810-3797026AD17DQ67546208-E1A7564B-BE05-4151-B916-FF8C24A55D9BQ67709098-F60A2816-7F25-48FA-AC8B-A24D80AF587CQ67841233-DF807574-7978-40C0-BBB4-F0656625E06CQ69086021-BBCF3B93-E209-4799-B2DD-15CDB78D22B8Q70676497-77F2A56C-6B37-4193-9AB8-FFF362A13CFCQ70866732-307D4964-B692-458F-B4DE-C6FE358238D8Q70963322-F71C355E-9FCF-404E-9358-07B1BD24B4F6Q71682086-248D1DC5-C2F7-4A1B-8C58-7E31862420A0Q71752745-7B87FC53-6E3E-4870-9535-CF5F6759BC07Q72680948-2BE1E694-B038-47CC-9E98-50D198E0FECFQ73847213-4DAA95EB-A7DF-4230-A4EF-6670825FBC46Q85411151-96459914-63DB-421A-9968-8F2DC07DC688Q90585109-9298DD93-4DA5-4605-9E26-6A924BB5B42B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Frans van Overveld
@ast
Frans van Overveld
@en
Frans van Overveld
@es
Frans van Overveld
@nl
type
label
Frans van Overveld
@ast
Frans van Overveld
@en
Frans van Overveld
@es
Frans van Overveld
@nl
prefLabel
Frans van Overveld
@ast
Frans van Overveld
@en
Frans van Overveld
@es
Frans van Overveld
@nl
P106
P31
P496
0000-0003-0352-9113